Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07524322 · ClinicalTrials.gov registry record · Phase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
A Phase 1 study, sponsored by Regor Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT07524322: Recruiting Phase 1 study, sponsored by Regor Pharmaceuticals.
NCT07524322 is a Phase 1 study that is actively recruiting participants, run by Regor Pharmaceuticals. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07524322, a Phase 1 study, is actively recruiting participants, sponsored by Regor Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
Interventions
- DRUG RGT-490
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07524322
The ClinicalTrials.gov registry entry for NCT07524322 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regor Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RGT-490 is the first listed.
NCT07524322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07524322 about?
NCT07524322 is a clinical study titled "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors". This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors i...
What is the current status of trial NCT07524322?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2026-06. Estimated completion is 2028-10.
What interventions are being tested in trial NCT07524322?
The interventions under investigation include: RGT-490 (DRUG).
Who is sponsoring clinical trial NCT07524322?
This trial is sponsored by Regor Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.